Please assess the completion status of the following clinical trial:

Trial Title: Phase II Cancer Vaccine Trial for Patients With Follicular Lymphoma

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~1. Age 18 years and older~2. Histologically confirmed (by WHO classification) untreated and relapsed indolent non-Hodgkin's B-cell lymphoma of low-grade follicular, marginal zone, lymphoplasmocytic or small lymphocytic subtypes.~3. Stage III/IV~4. Adequate bone marrow function (leukocyte count\>2,0, neutrophil count\>1.0, platelets\>50)~5. Two or more separate lymph nodes \> 1,5 cm available for biopsy or treatment.~6. Measurable disease present other than biopsy site and injection site(s).~7. Required wash-out period after previous treatment: Chemotherapy - 8 weeks, Radiotherapy - 4 weeks, Rituximab - 12 weeks~8. WHO status 0-1~9. Life expectancy of more than 6 months~10. Written informed consent~11. Able to comply with the treatment protocol -~Exclusion Criteria:~1. Patients with progressive lymphoma in need of systemic therapy or standard dose irradiation.~2. Chronic bacterial, viral or fungal infection~3. Pre-existing autoimmune or antibody mediated disease including: systemic lupus, erythematosus, rheumatoid arthritis, multiple sclerosis, Sjogren's syndrome, autoimmune thrombocytopenia, but excluding controlled thyroid disease, or the presence of autoantibodies without clinical autoimmune disease.~4. Known history of HIV~5. Central nervous system involvement of lymphoma~6. Current anticoagulant therapy which can not safely be paused during treatment injections (ASA \< 325 mg/day allowed)~7. Pregnancy -

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Radiotherapy , rituximab and DC (Type: EXPERIMENTAL): Treatment repeated 3 times and targeting different lymph nodes

Based on this trial design, predict the completion outcome and termination type (if applicable).